The European medicines watchdog on Friday approved the use of Moderna's coronavirus vaccine for children aged 12 to 17, making it the second jab for adolescents for use on the continent. "The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above," the European Medicines Agency (EMA) said, using Moderna's brand name.